HEMATOLOGY

We are dedicated to advancing clinical research in haematology, focusing on the diagnosis, treatment, and management of blood disorders and malignancies. Our efforts support the development of innovative therapies aimed at improving outcomes for patients with a broad spectrum of haematological conditions, from benign blood disorders to complex hematologic cancers.

We collaborate closely with leading haematologists, oncologists, and research centers to conduct high-quality clinical trials that adhere to global standards, emphasizing patient safety and scientific rigor.

hematology

Core Areas of Research:

  • Leukemias (Acute Myeloid Leukemia [AML], Acute Lymphoblastic Leukemia [ALL], Chronic Myeloid Leukemia [CML], Chronic Lymphocytic Leukemia [CLL])
  • Lymphomas (Hodgkin's and Non-Hodgkin's Lymphoma)
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Hemophilia and Coagulation Disorders
  • Sickle Cell Disease and Thalassemia
  • Bone Marrow and Stem Cell Transplantation
  • Platelet Disorders and Anemias
  • Iron Overload and Other Metabolic Blood Disorders

Research Capabilities at Tupalin Research:

  • Access to specialized haematology treatment centers with advanced laboratory and transfusion facilities
  • Conduct of early-phase to late-phase clinical trials including targeted therapies, immunotherapies, CAR-T cell therapy, and gene therapies
  • Central Laboratory Services equipped for hematologic biomarkers, flow cytometry, cytogenetics, and molecular diagnostics
  • Electronic Data Capture (EDC) systems optimized for complex haematology trial data and longitudinal monitoring
  • IVRS/IWRS Systems for subject randomization, dose management, and adaptive trial protocols
  • CTMS for efficient trial tracking, regulatory compliance, and data integrity
  • Collaboration with transplant units for studies on conditioning regimens, graft-versus-host disease (GVHD) prevention, and supportive care

Our Commitment:

We strive to accelerate the discovery and availability of life-changing treatments in haematology. Our patient-centric approach and rigorous scientific methodology ensure that every clinical trial we conduct advances the understanding and management of blood diseases, offering hope to patients and families worldwide.